NGF variants
AssigneeGenentech, Inc.
InventorsLeonard G. Presta, Roman Urfer, John W. Winslow
Life of this patent
Estimating the term…
Abstract
NGF variants which have trkC-binding activity and trkC-signal inducing activity are provided. The variants optionally have trkA or trkB binding and signal induction activity. The NGF variants of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the NGF variant neurotrophins are also provided.
Claims21
An NGF variant comprising NGF (SEQ ID NO:
- 1) having a single-amino-acid-substitution at amino acid positions G23, H84, and either V18 or V20 that impart trkC binding, wherein the variant binds trkC.
An NGF variant consisting essentially of amino acids 1 to 117, 1 to 118, 1 to 119 or 1 to 120 of NGF (SEQ ID NO. 1) having a single-amino-acid-substitution at amino acid positions V18, V20, G23, H84 and either F86 or T81 or both that impart trkC binding, wherein the variant binds trkC.
Dependencies are inferred from the claim text.